
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular is a financially stable medical device company that is actively seeking growth opportunities through potential M&A activities and new market expansion. With a strong track record of operational performance and a focus on open vascular and cardiac surgery, the company is well-positioned to continue its growth trajectory in the coming years. Additionally, their efforts to comply with EU regulations and increase their sales force demonstrate a commitment to sustained growth through both organic and strategic means.
Bears say
LeMaitre Vascular is expected to continue delivering consistent double-digit organic top line growth, with material margin expansion and strong cash flow, leading to a 25x multiple to our FY/26 adjusted EBITDA estimate and a $275 million net cash assumption in 12 months from now. Despite potential short-term weakness, the company has a solid balance sheet with $367 million in cash and marketable securities and only $169 million in debt, and is making strong progress in international regulatory approvals, including securing Canada and expected launches in Korea, Brazil, Vietnam, and India in 2027 for its largest product, Artegraft.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares